Haemophilias A and B

The haemophilias are inherited disorders in which one of the coagulation factors is deficient. Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's disease is much more common. Rare defects can occur in any of the coagulation factors. In the past, men with haemophilia were likely to die in their youth. With advances in diagnosis, and especially with development of safe and effective treatment, affected individuals can now look forward to a normal life expectancy. Complications of the disorder, particularly the development of antibodies that make treatment ineffective, and of treatment, such as transfusion-transmitted infections, have taken a severe toll on these patients. The future holds the realistic possibility of gene therapy. However, we must not forget that haemophilia is a worldwide disorder that requires significant economic resources not available for the majority.

[1]  P. Petrini,et al.  Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  J. Lusher Inhibitors in young boys with haemophilia. , 2000, Bailliere's best practice & research. Clinical haematology.

[3]  P. Giangrande,et al.  Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  D. Dimichele,et al.  Gene therapy ethics and haemophilia: an inevitable therapeutic future? , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  G. Dusheiko,et al.  The natural history and antiviral treatment of hepatitis C in haemophilia , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  J. Lusher Early treatment with recombinant factor VIIa results in greater efficacy with less product , 1998, European journal of haematology. Supplementum.

[7]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[8]  K. Khair,et al.  Complications experienced with central venous catheters in children with congenital bleeding disorders , 1997, British journal of haematology.

[9]  K. Khair,et al.  The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.

[10]  E. Chen,et al.  Characterization of the human factor VIII gene , 1984, Nature.

[11]  J. Lusher,et al.  Perinatal management of newborns with haemophilia , 2001, British journal of haematology.

[12]  R. Ljung,et al.  Anaphylactoid reactions and nephrotic syndrome – a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  V. Blanchette,et al.  Central venous access catheters in children with haemophilia. , 1996, Blood Coagulation and Fibrinolysis.

[14]  P. Giangrande,et al.  Increased bleeding associated with protease inhibitor therapy in HIV‐positive patients with bleeding disorders , 1999, British journal of haematology.

[15]  D. DiMichele,et al.  Inhibitors: resolving diagnostic and therapeutic dilemmas , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  R. Spicer,et al.  Implanted vascular access devices (ports) in children: complications and their prevention , 2002, Pediatric Surgery International.

[17]  A D Shapiro,et al.  Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.

[18]  E. Briët,et al.  [Hemophilia B Leyden]. , 1982, Nederlands tijdschrift voor geneeskunde.

[19]  C. Sabin,et al.  Outcome of orthotopic liver transplantation in patients with haemophilia , 1998, Gut.

[20]  F. Rodeghiero,et al.  Congenital von Willebrand disease type I: definition, phenotypes, clinical and laboratory assessment. , 2001, Best practice & research. Clinical haematology.

[21]  R. Miller,et al.  Somatic gene therapy for haemophilia: Some counselling issues for today and tomorrow , 2002 .

[22]  M. Ekman,et al.  Tolerance induction using the Malmö treatment model 1982–1995 , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[24]  Kessler,et al.  Bleeding episodes in HIV‐positive patients taking HIV protease inhibitors: a case series , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  P. Mannucci,et al.  A clinicopathological study of liver disease in haemophiliacs. , 1978, Journal of clinical pathology.

[26]  Mannucci,et al.  A prospective clinical trial of implantable central venous access in children with haemophilia , 1998, British journal of haematology.

[27]  J. Craske,et al.  AN OUTBREAK OF HEPATITIS ASSOCIATED WITH INTRAVENOUS INJECTION OF FACTOR-VIII CONCENTRATE , 1975, The Lancet.

[28]  Wilde Protease inhibitor therapy and bleeding , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  K. Fischer,et al.  Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  J. V. van Mourik,et al.  Tissue Distribution of Factor VIII Gene Expression In Vivo – A Closer Look , 2001, Thrombosis and Haemostasis.

[31]  Stylianos E. Antonarakis,et al.  Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A , 1993, Nature Genetics.

[32]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[33]  P. Giangrande,et al.  The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993–2003 , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  M. Colombo,et al.  Asymptomatic liver disease in haemophiliacs. , 1975, Journal of clinical pathology.

[35]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[36]  M. Siimes,et al.  Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[37]  R. Ljung,et al.  Normal vaginal delivery is to be recommended for haemophilia carrier gravidae , 1994, Acta paediatrica.

[38]  B. Cohen,et al.  Commercial factor VIII associated hepatitis, 1974–75, in the United Kingdom: a retrospective survey , 1978, Journal of Hygiene.

[39]  C. Kessler,et al.  The molecular basis of haemophilia B , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  A. Widell,et al.  Clinical spectrum of hepatitis C‐related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease , 2001, British journal of haematology.

[41]  P. Green,et al.  Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions. , 1993, Human molecular genetics.

[42]  C. Hay,et al.  PROGRESSIVE LIVER DISEASE IN HAEMOPHILIA: AN UNDERSTATED PROBLEM? , 1985, The Lancet.

[43]  C. Sabin,et al.  Assessing the effectiveness and cost‐effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease , 1998, Journal of internal medicine.

[44]  J. Goudemand,et al.  Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. , 2001, Best practice & research. Clinical haematology.

[45]  J. Astermark,et al.  The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[46]  B. Evatt,et al.  Haemophilia 2002: emerging risks of treatment , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[47]  P. Green,et al.  Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. , 2002, Blood.

[48]  P. Mannucci,et al.  Rare coagulation deficiencies , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[49]  Damiano,et al.  Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[50]  D. Schaid,et al.  Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. , 1994, Human molecular genetics.

[51]  C. Quinn,et al.  Catheter-related deep venous thrombosis in children with hemophilia. , 2001, Blood.

[52]  Ockelford,et al.  The use of central venous catheters (portacaths) in children with Haemophilia , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[53]  C. Prowse,et al.  Human Parvovirus B19 and Blood Products , 1997, Vox sanguinis.

[54]  G. Buchanan Factor concentrate prophylaxis for neonates with hemophilia. , 1999, Journal of pediatric hematology/oncology.

[55]  H. Roehl,et al.  Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. , 2003, Blood.

[56]  A. Miners,et al.  Experience of prophylaxis treatment in children with severe haemophilia , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[57]  V. Blanchette,et al.  Health‐related quality‐of‐life treatments for severe haemophilia: utility measurements using the Standard Gamble technique , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[58]  J. Oldenburg,et al.  NovoSeven® in immune tolerance therapy , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[59]  E. Thorland,et al.  Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[60]  K. Kurachi,et al.  Isolation and characterization of a cDNA coding for human factor IX. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[62]  D. Treco,et al.  Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. , 2001, The New England journal of medicine.

[63]  H. Jürgens,et al.  When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study , 1999, European journal of pediatrics.

[64]  C. Lee Women and inherited bleeding disorders: menstrual issues. , 1999, Seminars in hematology.

[65]  P. Petrini What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B , 2001 .

[66]  Mannucci Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[67]  C. Steer,et al.  In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides , 1998, Nature Medicine.

[68]  Christine A. Lee,et al.  Inhibitors in Patients with Haemophilia , 2002 .

[69]  D. Jolly,et al.  Animal Testing of Retroviral-Mediated Gene Therapy for Factor VIII Deficiency , 1999, Thrombosis and Haemostasis.

[70]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[71]  C. Barnes,et al.  Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[72]  F. Rosendaal,et al.  The natural history of chronic hepatitis C in haemophiliacs , 1996, British journal of haematology.

[73]  C. Mazurier,et al.  Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[74]  C. Steer,et al.  Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[75]  K. Pasi Gene therapy for haemophilia , 2001, Bailliere's clinical haematology.

[76]  P. Jones,et al.  The early history of haemophilia treatment: a personal perspective , 2000, British journal of haematology.

[77]  J. Gill,et al.  Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.

[78]  E. Rodríguez‐Merchán Common orthopaedic problems in haemophilia , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[79]  D. Brettler 8 Inhibitors in congenital haemophilia , 1996 .

[80]  C. Kessler,et al.  Management of haemophilia B patients with inhibitors and anaphylaxis , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[81]  End-stage liver disease in persons with hemophilia and transfusion-associated infections. , 2002 .

[82]  F. Beek,et al.  Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia , 2001, British journal of haematology.

[83]  K. Pasi,et al.  Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate , 1996, British journal of haematology.

[84]  M. Baiget,et al.  Modifier genes in haemophilia: their expansion in the human genome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[85]  P. Giangrande,et al.  Treatment of haemophilia in the United Kingdom 1981-1996. , 2001 .

[86]  F. Rodeghiero von Willebrand disease: still an intriguing disorder in the era of molecular medicine , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[87]  H. Roberts,et al.  Rationale for the use of high dose rFVIIa in a high‐titre inhibitor patient with haemophilia B during major orthopaedic procedures , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.